London
Roots Analysis has announced the
addition of “Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and
Finished Dosage Forms, 2020-2030” report
to its list of offerings.
Manufacturing
live biotherapeutic products is both technically challenging and financially
demanding; as a result, innovator firms are becoming increasingly reliant on
contract service providers to access specialized facilities and optimize
overall costs.
To order this 300+ page report, which features 140+ figures
and 125+ tables, please visit this link
Key
Market Insights
Over
25 players claim to provide microbiome-based live biotherapeutics contract manufacturing
More
than 80% of the companies engaged in this domain are mid-sized and large firms; examples of firms established in 2019
include Arranta Bio and BacThera (a Lonza and Chr. Hansen joint venture).
Further, nearly 50% of the CMOs have established the necessary expertise for
handling both anaerobic and aerobic strains.
35+ manufacturing facilities focused on live biotherapeutics
have been established worldwide
Majority (~55%) of the manufacturing facilities are located in Europe, followed by North America. Prominent manufacturing hubs in the Europe include (in
decreasing order of number of manufacturing facilities) the UK, France, the Netherlands,
Italy, Germany, Switzerland, and Sweden.
Approximately 88% of the total installed capacity is dedicated
to commercial scale manufacturing
Whereas, rest (~10%) of the capacity is being used for preclinical / clinical
scale manufacturing of microbiome products. In addition, over 60% of the total
current global, installed manufacturing capacity is installed in Europe.
Over
170 registered clinical trials involved the use of microbiome-based live
biotherapeutics
Majority of these studies are being conducted at various
hospitals / centers across the US. Examples of leading non-industry players
include (in decreasing order of number of trials) University of
California, National Institute of Allergy and Infectious Diseases, Radboud
University, and The University of Texas Health Science Center.
The
global clinical demand for microbiome-based live biotherapeutic products is anticipated to grow at a CAGR
of 23%, between 2020 and 2030
By 2030, over 31,000 patients are estimated to be enrolled in
the clinical trials involving the use of microbiome-based live biotherapeutics.
Industry players are anticipated to contribute majority (over 60%) of the
demand in the short-term as well as long-term.
Several big pharma players are actively engaged in the microbiome
live biotherapeutics domain
In fact, leading pharmaceutical companies have partnered with
smaller business entities to develop manufacturing capabilities related to
microbiome-based therapies / diagnostics. Examples of such small ventures with
players with in-house capability include (in alphabetical order) Assembly
Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.
By 2030, North America and Europe are
anticipated to capture over 85% of the market opportunity
In
terms of type of product manufactured, APIs currently represent the highest
share (58%); this trend is unlikely to change in the foreseen future.
To request a sample
copy / brochure of this report, please visit this link
Key Questions Answered
§
§
§
§ What is the current, installed contract manufacturing capacity for live
biotherapeutics?
§
§
§
§
§
The USD 300 million (by 2030) financial opportunity
within the microbiome contract manufacturing market has been analysed across
the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The
report features inputs from eminent industry stakeholders, according to whom the
microbiome therapeutics contract manufacturing services market is likely to
witness substantial growth in the foreseen future. The report includes detailed
transcripts of discussions held with the following experts:
§
§
§
§
§
§
§
§
The
research covers detailed profiles brief profiles of several companies (including
those listed below); each profile features an overview of the company, its
financial information (if available),
microbiome-related service portfolio, facilities dedicated to microbiome
manufacturing, and an informed future outlook.
§
§
§
§
§
§
§ Paragon
Bioservices (a unit of Catalent Biologics)
§
For
additional details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You
may also be interested in the following titles:
1.
2.
Contact:
Gaurav
Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com